11/5/2026

speaker
Operator
Conference Call Operator

Hello and welcome to BD's fourth quarter and full year fiscal 2026 earnings call. At the request of BD, today's call is being recorded and will be available for replay on BD's investor relations website, investors.bd.com or by phone at 800-677-7085 for domestic calls and area code plus 1-402-220-0665 for international calls. For today's call, all parties have been placed in a listen-only mode until the question-and-answer session. I will now turn the call over to Shawn Bevec, Senior Vice President, Investor Relations.

speaker
Shawn Bevec
Senior Vice President, Investor Relations

Good morning and welcome to BD's earnings call. I'm Shawn Bevec, Senior Vice President of Investor Relations. Thank you for joining us. This call is being made available via audio webcast at BD.com. Earlier this morning, BD released its results for the fourth quarter and full year fiscal 26. The press release and presentation can be accessed on the IR website at investors.vd.com. Leading today's call are Tom Polen, VD's Chairman, Chief Executive Officer and President, and Vitor Roque, Executive Vice President and Chief Financial Officer. Before we get started, I want to remind you that we will be making forward-looking statements. You can read the disclaimer in our earnings release and the disclosures in our SEC filings on our Investor Relations website. Unless otherwise specified, all comparisons will be made on a year-on-year basis versus the relevant fiscal period. Revenue percentage changes are on an FX neutral basis unless otherwise noted. Also, references to adjusted EPS refer to adjusted diluted EPS. The financials discussed here and included in the earnings release are presented on a continuing operations basis. Prior periods have been recast to reflect the spinoff of our life sciences business in combination with Waters which is accounted for as discontinued operations. Reconciliations between GAAP and non-GAAP measures are included in the appendices of our earnings release and presentation. With that, I will turn it over to Tom. Thank you, Shawn, and good morning, everyone.

speaker
Tom Polen
Chairman, Chief Executive Officer and President

Earlier today, we reported strong Q4 results with revenue of $5.3 billion, up 5.6%, and 27.3% growth in adjusted EPS to $4.15. For the full year, we delivered $19.5 billion in revenue, up 3.9%, and 6.7% growth in adjusted EPS to $12.70. Growth remained broad-based, with momentum across all our businesses. Excluding the Alaris prior year comparison, we delivered high single-digit revenue growth in Q4 and solid mid-single-digit growth for the full year. Growth was led by the key platforms where we've been investing – including Advanced Patient Monitoring, PureWIC, Advanced Tissue Regeneration, Biologic Drug Delivery and ROA Pharmacy Automation, all of which delivered double-digit growth with accretive margins in both Q4 and the full year. Importantly, Fiscal 26 marks a significant milestone, completing VD's transformation to a more focused medtech company with the separation of our life sciences business. New BD is doing exactly what we designed it to do, demonstrating the growth and earnings potential of our focused portfolio through commercial and innovation momentum across our key growth platforms, delivering strong operational execution and the expanding impact of BD excellence. Before we get into more details on the quarter, I want to highlight our recent landmark partnership with the U.S. government, which reflects BD's important role in the U.S. healthcare infrastructure and and a shared commitment to expand domestic manufacturing capacity and strengthen access to essential medical technologies. Through this agreement, we committed to invest $19 billion in the U.S. over several years, with $3 billion of the overall investment directed toward manufacturing expansion. Importantly, this does not represent incremental investment for BD, rather a reprioritization of investments toward the U.S. The partnership also provides relief from future tariffs imposed under Section 232 on covered BD products and inputs, subject to the final scope and implementation of any future Section 232 actions and BD's achievement of agreed milestones. We've already mobilized the organization and begun taking action to deliver on these commitments. Turning to our new BD strategy. We're seeing clear progress against our three strategic pillars, compete, innovate and deliver. Our growing commercial, innovation and operational capabilities are strengthening the quality of our growth while improving earnings power and cash flow. Starting with compete, we've been raising the bar on commercial execution across BD, investing in every part of the commercial flywheel. That spans talent, AI sales tools a disciplined sales process, and new pay-for-performance compensation plans, all powered by VD excellence and a relentless focus on solving customer challenges with speed and urgency. In Q4, this translated into measurable outcomes across the company. Within Connected Care, commercial execution continued to drive share gains and new adoption across all platforms. In advanced patient monitoring, Salesforce investments are driving uptake of Hemisphere Alta that contributed to strong capital growth in Q4. APM continues to perform well ahead of the deal model, generating one of its highest annual growth rates in the last 20 years, while significantly expanding margins under BD's ownership by applying BD excellence in APM manufacturing. Alaris finished the year with strong competitive momentum, gaining additional share in Q4 and more than 250 basis points for the full year. Dispensing also continued to gain share with strong Pixis Pro order momentum and a 95% attachment rate of our new Encata AI platform. This strong early adoption reflects high customer interest in our new BD AI platform and supports our strategy to build recurring software, analytics and AI revenue. In pharmacy automation, Incremental investments we made coming into the year are delivering results. We're seeing increased central fill win rates and an improving growth outlook aided by the recent U.S. launch of BDVMAX. We exited the year with strong commercial momentum, winning all six central fill opportunities we competed for in Q4 with VMAX attached to every sale, reinforcing the strength of our portfolio in the growing U.S. healthcare system central fill markets. In biopharma systems, we expanded our position in next-generation biologic drug delivery, including continued momentum in delivering GLP-1 therapies. In interventional, incremental commercial investments are translating to stronger growth, with PI accelerating each quarter throughout the year. In UCC, PURIC delivered another quarter of double-digit growth, driven by continued adoption, competitive wins, and momentum in the VA channels. Across the portfolio, we're seeing our commercial investments translate into stronger growth and competitive performance. We've added resources in priority areas, introduced new tools, applied BD excellence to commercial execution, and better aligned incentives with our growth priorities. These actions are raising execution across new BD. Our second priority is innovate. We're concentrating investments in attractive markets where healthcare needs BD most. and where we believe BD can create sustainable competitive advantage. This is in connected care, enabling the shift to newer low-cost settings and advancing the treatment of chronic disease. Earlier this year, we moved more R&D resources and decision-making closer to the businesses. We increased investments behind our six key growth platforms and our pipeline is expanding. We also deployed BD excellence into R&D this year and are introducing new products faster, having compressed launch times by an average of 10 months. In Q4, we received FDA approval for Liberty Tips StentCraft and we're seeing strong customer interest. In a market that's seen limited innovation for many years, Liberty brings enhanced ease of use, the broadest range of lengths and compelling clinical data, broadening BD's presence in the approximately $2 billion global venous market which is growing high single digits. We recently received 510K clearance for Phase X ST peristomal, a first-of-its-kind reservable mesh designed specifically for peristomal hernia repairs. It's an underserved market with significant unmet clinical needs. With the launch expected in the first half of fiscal 27, this innovation further expands our advanced tissue regeneration portfolio and strengthens our position in the $1.8 billion served market. Thank you so much for joining us. Through BD Excellence, we've built one of the most resilient supply chains in our industry, which combined with our scale has become a meaningful competitive advantage. In fiscal 26, we delivered approximately 8% gross productivity in our plants, with customer service levels above 90%. This was driven by more than 2,000 Kaizen events, resulting in higher manufacturing efficiencies and raw material savings, as well as ongoing network optimizations. We are also generating value from the $200 million cost-out program launched at the beginning of fiscal 26, with 100% of the savings now identified. Turning to capital allocation, our discipline framework remains unchanged. Importantly, we're seeing our operational progress translate into stronger cash generation. As free cash flow improves, so does our capacity to invest organically, return capital to shareholders, and pursue focused tuck-in M&A. This will continue to increase as we drive towards our 90% free cash flow conversion target over time. In summary, fiscal 26 was an important year for BD. We completed our portfolio transformation to a pure play med tech company. We strengthened execution and increasingly saw the benefits of the strategic choices and investments we've made over the last several years. Our differentiated growth platforms are strengthening our portfolio and expanding our opportunities for growth. We enter fiscal 27 with a more focused portfolio and we have confidence in the underlying trajectory of new BD and our path towards sustainable mid-single digit growth. Looking ahead, we see a compelling opportunity to combine that growth with continued earnings expansion and a step change in cash flow generation to drive long-term value creation. We are still early in realizing the full potential of new BD. and we look forward to laying out that opportunity in greater detail at our investor day on December 10th. With that, I'll turn it over to Vitor to provide more detail on our financial performance and guidance.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Investor presentation